Published in Sci Transl Med on April 30, 2014
Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches. Front Immunol (2014) 0.85
Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence? Front Public Health (2014) 0.84
Using humans to make a human leishmaniasis vaccine. Sci Transl Med (2014) 0.80
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine. Gene Ther (2015) 0.80
Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate. Antimicrob Agents Chemother (2015) 0.78
Post-Genomics and Vaccine Improvement for Leishmania. Front Microbiol (2016) 0.78
Targeting Dendritic Cells as a Good Alternative to Combat Leishmania spp. Front Immunol (2014) 0.76
HisAK70: progress towards a vaccine against different forms of leishmaniosis. Parasit Vectors (2015) 0.76
Prediction of T Cell Epitopes from Leishmania major Potentially Excreted/Secreted Proteins Inducing Granzyme B Production. PLoS One (2016) 0.76
Targeted Immunology for Prevention and Cure of VL. Front Immunol (2014) 0.75
Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration. Genome Biol (2016) 0.75
Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine. PLoS Negl Trop Dis (2017) 0.75
Cutaneous leishmaniasis. Lancet Infect Dis (2007) 9.32
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Patterns of auxin transport and gene expression during primordium development revealed by live imaging of the Arabidopsis inflorescence meristem. Curr Biol (2005) 6.35
PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis (2003) 5.32
Imaging plant growth in 4D: robust tissue reconstruction and lineaging at cell resolution. Nat Methods (2010) 4.47
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg Med Chem (2003) 3.21
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 2.81
The auxin signalling network translates dynamic input into robust patterning at the shoot apex. Mol Syst Biol (2011) 2.74
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Triosephosphate isomerase gene characterization and potential zoonotic transmission of Giardia duodenalis. Emerg Infect Dis (2003) 2.46
Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci U S A (2007) 2.41
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol (2006) 2.26
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Artemisone--a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl (2006) 2.09
Current scenario of drug development for leishmaniasis. Indian J Med Res (2006) 2.06
Pattern formation during de novo assembly of the Arabidopsis shoot meristem. Development (2007) 2.02
Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg (2010) 1.98
The homeotic protein AGAMOUS controls microsporogenesis by regulation of SPOROCYTELESS. Nature (2004) 1.98
Microsatellite analysis reveals genetic structure of Leishmania tropica. Int J Parasitol (2005) 1.98
Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol (2003) 1.96
Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol (2005) 1.84
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents (2003) 1.83
Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol (2007) 1.81
Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed Engl (2004) 1.80
TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem (2006) 1.80
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe (2013) 1.77
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Multilocus microsatellite typing (MLMT) reveals genetically isolated populations between and within the main endemic regions of visceral leishmaniasis. Microbes Infect (2007) 1.73
Retracted Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood (2007) 1.73
Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int (2011) 1.71
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
Inequalities in maternity care and newborn outcomes: one-year surveillance of births in vulnerable slum communities in Mumbai. Int J Equity Health (2009) 1.67
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop (2002) 1.64
Community mobilization in Mumbai slums to improve perinatal care and outcomes: a cluster randomized controlled trial. PLoS Med (2012) 1.63
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Multilocus microsatellite typing as a new tool for discrimination of Leishmania infantum MON-1 strains. J Clin Microbiol (2006) 1.58
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Outbreak of cutaneous leishmaniasis in northern Israel. J Infect Dis (2003) 1.57
Detection and identification of old world Leishmania by high resolution melt analysis. PLoS Negl Trop Dis (2010) 1.57
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med (2013) 1.54
Multilocus sequence typing and genetic structure of Cryptosporidium hominis from children in Kolkata, India. Infect Genet Evol (2006) 1.52
Wide geographic distribution of Cryptosporidium bovis and the deer-like genotype in bovines. Vet Parasitol (2006) 1.51
Long-lasting insecticidal nets fail at household level to reduce abundance of sandfly vector Phlebotomus argentipes in treated houses in Bihar (India). Trop Med Int Health (2008) 1.51
Insecticide susceptibility of Phlebotomus argentipes in visceral leishmaniasis endemic districts in India and Nepal. PLoS Negl Trop Dis (2010) 1.50
Analysis of ribosomal DNA internal transcribed spacer sequences of the Leishmania donovani complex. Microbes Infect (2005) 1.49
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49
Megaloblastic anemia in North Africa. Haematologica (2006) 1.48
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother (2006) 1.46
Cluster-randomised controlled trial of community mobilisation in Mumbai slums to improve care during pregnancy, delivery, postpartum and for the newborn. Trials (2008) 1.45
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother (2011) 1.45
Role of IL-10 and TGF-β in melanoma. Exp Dermatol (2015) 1.44
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents (2007) 1.39
Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res (2006) 1.39
Phylogeny and evolution of medical species of Candida and related taxa: a multigenic analysis. J Clin Microbiol (2004) 1.38
Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes. J Biol Chem (2005) 1.37
Comparative microsatellite typing of new world leishmania infantum reveals low heterogeneity among populations and its recent old world origin. PLoS Negl Trop Dis (2011) 1.36
2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype. J Med Chem (2008) 1.36
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg (2005) 1.36
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 1.35
Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg (2010) 1.34
Practical approach for typing strains of Leishmania infantum by microsatellite analysis. J Clin Microbiol (2002) 1.33
Leishmania donovani suppresses activated protein 1 and NF-kappaB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. Infect Immun (2002) 1.32
Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl Trop Dis (2010) 1.31
Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine (2005) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med (2012) 1.29
Polymerase chain reaction using noninvasively obtained samples, for the detection of Leishmania infantum DNA in dogs. J Infect Dis (2004) 1.28
Lipopeptide structure determines TLR2 dependent cell activation level. FEBS J (2005) 1.28
Detection, differentiation, and quantitation of pathogenic leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol (2003) 1.28
Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol (2005) 1.28
Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother (2002) 1.28
Maternal and neonatal health expenditure in Mumbai slums (India): a cross sectional study. BMC Public Health (2011) 1.26
The role of mechanical forces in plant morphogenesis. Annu Rev Plant Biol (2011) 1.25
Leishmania tropica in rock hyraxes (Procavia capensis) in a focus of human cutaneous leishmaniasis. Am J Trop Med Hyg (2010) 1.25
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother (2010) 1.23
Differentiation and gene flow among European populations of Leishmania infantum MON-1. PLoS Negl Trop Dis (2008) 1.23
Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur J Immunol (2005) 1.22
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21
Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol (2003) 1.21
Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 1.21
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis (2007) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19